Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Non-cash Items: 2021-2025

Historic Non-cash Items for Organogenesis Holdings (ORGO) over the last 4 years, with Sep 2025 value amounting to $6.3 million.

  • Organogenesis Holdings' Non-cash Items rose 89.83% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 89.83%. This contributed to the annual value of $2.5 million for FY2024, which is 75.45% down from last year.
  • As of Q3 2025, Organogenesis Holdings' Non-cash Items stood at $6.3 million, which was up 13.73% from $5.5 million recorded in Q2 2025.
  • Organogenesis Holdings' 5-year Non-cash Items high stood at $38.5 million for Q4 2021, and its period low was $1.5 million during Q1 2023.
  • In the last 3 years, Organogenesis Holdings' Non-cash Items had a median value of $5.5 million in 2025 and averaged $5.7 million.
  • As far as peak fluctuations go, Organogenesis Holdings' Non-cash Items plummeted by 94.17% in 2022, and later surged by 357.33% in 2023.
  • Quarterly analysis of 5 years shows Organogenesis Holdings' Non-cash Items stood at $38.5 million in 2021, then plummeted by 94.17% to $2.2 million in 2022, then spiked by 357.33% to $10.3 million in 2023, then tumbled by 75.45% to $2.5 million in 2024, then surged by 89.83% to $6.3 million in 2025.
  • Its Non-cash Items was $6.3 million in Q3 2025, compared to $5.5 million in Q2 2025 and $12.6 million in Q1 2025.